Human IL-1ra/IL-1F3 DuoSet ELISA DY280-05 from R&D Systems, a Bio-Techne Brand

Product Specs
ItemHuman IL-1ra/IL-1F3 DuoSet ELISA
CompanyR&D Systems, a Bio-Techne Brand
Price $450.00Supplier Page View Company Product Page
Catalog NumberDY280-05
NCBI Gene AliasesDIRA, ICIL-1RA, IL-1RN, IL-1ra, IL-1ra3, IL1F3, IL1RA, IRAP, MVCD4
NCBI Full Gene Nameinterleukin 1 receptor antagonist
StorageStore the unopened product at 2 - 8 °C. Do not use past expiration date
Detection TargetIL-1ra/IL-1F3
ReactivityHuman
Detection Range39.10 - 2500 pg/mL
ApplicationsELISA
Quantity1 Kit (for 5 Plates) (also 1 Kit (for 15 Plates))

614 McKinley Place N.E.

Minneapolis, Minnesota 55413

United States

Phone: 1 (800) 343-7475
1 (612) 379-2956

Fax: 1 (612) 656-4400

(2) Cytokine profiles dynamics in COVID-19 patients: a longitudinal analysis of disease severity and outcomesScientific reportsApril 23, 2025Ghaffarpour S, Ghazanfari T, Ardestani SK, Naghizadeh MM, Vaez Mahdavi MR, Salehi M, Majd AMM, Rashidi A, Chenary MR, Mostafazadeh A, et al.

(4) Distinct inflammatory profiles in mustard lung: A study of sulfur mustard-exposed patients with serious pulmonary complicationsInternational immunopharmacologyJanuary 27, 2025Pourfarzam S, Ardestani SK, Jamali T, Ghazanfari H, Naghizadeh MM, Faghihzadeh S, Yaraee R, Ghazanfari Z, Ghazanfari T.

(5) Interleukin-1β induces trained innate immunity in human hematopoietic progenitor cells in vitroStem cell reportsDecember 10, 2024Flores-Gomez D, Hobo W, van Ens D, Kessler EL, Novakovic B, Schaap NPM, Rijnen WHC, Joosten LAB, Netea MG, Riksen NP, et al.

(6) Exploring the innate immune response in polycystic liver diseaseCytokineDecember 1, 2024Duijzer R, Dalloyaux D, Boerrigter MM, Lemmers H, Dijkstra H, van Emst L, Te Morsche RHM, Jaeger M, Joosten LAB, Drenth JPH.

(7) Long-Lasting Enhanced Cytokine Responses Following SARS-CoV-2 BNT162b2 mRNA VaccinationVaccinesJuly 3, 2024Cabău G, Badii M, Mirea AM, Gaal OI, van Emst L, Popp RA, Crișan TO, Joosten LAB.

(8) Leishmania braziliensis enhances monocyte responses to promote anti-tumor activityCell reportsMarch 26, 2024Dos Santos JC, Moreno M, Teufel LU, Chilibroste S, Keating ST, Groh L, Domínguez-Andrés J, Williams DL, Ma Z, Lowman DW, et al.

(10) Dimethyl itaconate induces long-term innate immune responses and confers protection against infectionCell reportsJune 27, 2023Ferreira AV, Kostidis S, Groh LA, Koeken VACM, Bruno M, Baydemir I, Kilic G, Bulut Ö, Andriopoulou T, Spanou V, et al.

(11) Prevention of M2 polarization and temporal limitation of differentiation in monocytes by extracellular ATPBMC immunologyJune 23, 2023Scherr BF, Reiner MF, Baumann F, Höhne K, Müller T, Ayata K, Müller-Quernheim J, Idzko M, Zissel G.

(12) TGF-β is elevated in hyperuricemic individuals and mediates urate-induced hyperinflammatory phenotype in human mononuclear cellsArthritis research & therapyFebruary 27, 2023Klück V, Cabău G, Mies L, Bukkems F, van Emst L, Bakker R, van Caam A, HINT consortium, Crişan TO, Joosten LAB.

(13) Effect of exogenous IL-37 on immune cells from a patient carrying a potential IL37 loss-of-function variant: A case studyCytokineFebruary 1, 2023Teufel LU, van der Made CI, Klück V, Simons A, Hoischen A, Vernimmen V, Joosten LAB, Arts RJW.

(14) Ventilatory support and inflammatory peptides in hospitalised patients with COVID-19: A prospective cohort trialPloS oneJanuary 1, 2023Gysan MR, Milacek C, Bal C, Zech A, Brugger J, Milos RI, Antoniewicz L, Idzko M, Gompelmann D.

(15) Exercise training-induced changes in immunometabolic markers in youth badminton athletesScientific reportsSeptember 15, 2022Rossi FE, Maldonado AJ, Cholewa JM, Ribeiro SLG, de Araújo Barros CA, Figueiredo C, Reichel T, Krüger K, Lira FS, Minuzzi LG.

(17) Clinical and biological markers for predicting ARDS and outcome in septic patientsScientific reportsNovember 22, 2021Villar J, Herrán-Monge R, González-Higueras E, Prieto-González M, Ambrós A, Rodríguez-Pérez A, Muriel-Bombín A, Solano R, Cuenca-Rubio C, Vidal A, et al.

(19) Pulmonary function changes in older adults with and without metabolic syndromeScientific reportsAugust 30, 2021Brandao-Rangel MAR, Moraes-Ferreira R, Oliveira-Junior MC, Santos-Dias A, Bachi ALL, Gabriela-Pereira G, de Oliveira Freitas S, Araújo-Rosa AC, Oliveira LVF, Frison CR, et al.

(20) Impact of IL-1β and the IL-1R antagonist on relapse risk and survival in AML patients undergoing immunotherapy for remission maintenanceOncoImmunologyAugust 9, 2021Hanna Grauers Wiktorin, Ebru Aydin, Karin Christenson, Nuttida Issdisai, Fredrik B. Thorén, Kristoffer Hellstrand, Anna Martnersupernatants were collected and assayed for IL-1β and IL-1RA using ELISA (R&D systems, DY201, and R&D systems, DY280-05, respectively) according to the manufacturer’s instructions. Statistics Changes in IL-1β and IL-1RA

IL-1ra/IL-1F3 ELISA